Przejdź do zawartości
Merck

SAB4200047

Sigma-Aldrich

Anti-BRD7 antibody, Rat monoclonal

clone BRM 2D3, purified from hybridoma cell culture

Synonim(y):

Anti-BP75, Anti-Bromodomain containing 7, Anti-CELTIX1, Anti-NAG4, Monoclonal Anti-BRD7 antibody produced in rat

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Kod UNSPSC:
12352203
NACRES:
NA.41

pochodzenie biologiczne

rat

białko sprzężone

unconjugated

forma przeciwciała

purified from hybridoma cell culture

rodzaj przeciwciała

primary antibodies

klon

BRM 2D3, monoclonal

Postać

buffered aqueous solution

masa cząsteczkowa

antigen ~80 kDa

reaktywność gatunkowa

rat, mouse, monkey, human, bovine, canine

opakowanie

antibody small pack of 25 μL

metody

immunocytochemistry: suitable
immunoprecipitation (IP): suitable
western blot: 0.5-1.0 μg/mL using HeLa cells extract

izotyp

IgG2a

numer dostępu UniProt

Warunki transportu

dry ice

temp. przechowywania

−20°C

docelowa modyfikacja potranslacyjna

unmodified

informacje o genach

human ... BRD7(29117)

Opis ogólny

Monoclonal Anti-BRD7 (rat IgG2a isotype) is derived from the hybridoma BRM 2D3 produced by the fusion of mouse myeloma cells (P3X63Ag8.653) and splenocytes from rat immunized with a fusion protein expressing a fragment of human BRD7. Bromodomain containing (BRD7) is a novel bromodomain gene.

Zastosowanie

Monoclonal Anti-BRD7 antibody produced in rat has been used in several immunochemical techniques including
  • immunoblotting
  • immunoprecipitation
  • immunocytochemistry

Działania biochem./fizjol.

Bromodomain containing (BRD7) inhibits cell growth and cell cycle progression by transcriptional regulation of some cell cycle-related genes as well as some important molecules involved in ras/mitogen-activated protein kinase(MEK)/extracellular-signal-regulated kinase (ERK) and retinoblastoma tumor suppressor protein (RB)/ E2 factor (E2F) pathways. Its transcriptional down regulation has been shown to be critical to the pathogenesis of nasopharyngeal carcinoma (NPC). Specifically, DNA methylation decreases the expression of BRD7 in NPC cells. Furthermore, DNA methylation of BRD7 promoter is increased in the tumor and in matched blood samples from NPC patients than in blood samples from healthy individuals. Therefore, it has been suggested that DNA methylation of BRD7 promoter might act as a potential diagnostic marker in NPC.

Postać fizyczna

Solution in 0.01M phosphate buffered saline pH 7.4, containing 15 mM sodium azide.

Oświadczenie o zrzeczeniu się odpowiedzialności

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
This page may contain text that has been machine translated.

Nie możesz znaleźć właściwego produktu?  

Wypróbuj nasz Narzędzie selektora produktów.

Kod klasy składowania

10 - Combustible liquids

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Promoter methylation inhibits BRD7 expression in human nasopharyngeal carcinoma cells
Liu H, et al.
BMC Cancer, 8(1), 253-253 (2008)
The transcriptional regulation role of BRD7 by binding to acetylated histone through bromodomain
Cong P, et al.
Journal of Cellular Biochemistry, 97(4), 882-892 (2006)
Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis
Chou J, et al.
Head & Neck, 30(7), 946-963 (2008)
Junichi Yamamoto et al.
Nature chemical biology, 16(11), 1208-1217 (2020-09-23)
The immunomodulatory drug (IMiD) thalidomide and its derivatives lenalidomide and pomalidomide are therapeutic agents used in the treatment of multiple myeloma. Although pomalidomide offers considerable clinical benefits to patients with lenalidomide-resistant multiple myeloma, the molecular mechanisms underlying its superior efficacy

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej